Overview

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The goal of this proposal is to produce and test high specific activity Ultratrace iobenguane I 123 in normal human volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Bennett Chin
Collaborators:
Molecular Insights Pharmaceuticals
National Cancer Institute (NCI)
Treatments:
3-Iodobenzylguanidine